LXRX: Lexicon Pharmaceuticals, Inc.
About
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Current Value
$0.881 Year Return
Current Value
$0.881 Year Return
Key Details
Market Cap
$318.44M
P/E Ratio
-1.18
1Y Stock Return
-18.44%
1Y Revenue Growth
884.75%
Dividend Yield
0.00%
Price to Book
1.8
Strategies that include LXRX
Stock's related to LXRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NTLA | 48.88% | $1.44B | -50.35% | 0.00% |
| BEAM | 47.70% | $2.09B | -9.52% | 0.00% |
| ADPT | 45.95% | $661.15M | +6.16% | 0.00% |
| VIR | 45.38% | $954.40M | -26.51% | 0.00% |
| JOBY | 44.89% | $4.84B | +13.24% | 0.00% |
| CRSP | 44.71% | $4.01B | -30.49% | 0.00% |
| ABCL | 44.48% | $800.44M | -37.56% | 0.00% |
| RCKT | 42.92% | $1.20B | -39.83% | 0.00% |
| NTCT | 41.22% | $1.52B | +3.77% | 0.00% |
| PACB | 40.40% | $471.05M | -79.23% | 0.00% |
| STHO | 40.09% | $150.51M | -5.99% | 0.00% |
| CLFD | 39.68% | $398.66M | +4.48% | 0.00% |
| RCUS | 39.14% | $1.33B | +5.07% | 0.00% |
| PLRX | 39.09% | $778.32M | -9.55% | 0.00% |
| RMR | 39.01% | $368.58M | -6.46% | 7.97% |
| DBRG | 38.40% | $2.15B | -23.92% | 0.32% |
| LPRO | 38.32% | $738.78M | +2.65% | 0.00% |
| CLNE | 38.14% | $589.93M | -23.92% | 0.00% |
| BRSP | 38.09% | $806.64M | -3.86% | 12.20% |
| BIGC | 37.89% | $473.42M | -31.75% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CLX | 0.07% | $20.81B | +20.66% | 2.88% |
| ORKA | 0.10% | $780.47M | +82.82% | 0.00% |
| KLG | 0.23% | $1.48B | +45.15% | 3.71% |
| BACK | -0.32% | $1.76M | -32.90% | 0.00% |
| KR | -0.39% | $42.03B | +35.08% | 2.11% |
| LUMO | -0.42% | $37.45M | +41.97% | 0.00% |
| PENG | 0.44% | $911.79M | +4.97% | 0.00% |
| XOS | -0.45% | $30.51M | -57.24% | 0.00% |
| PGR | -0.53% | $149.10B | +57.29% | 0.45% |
| RDDT | 0.61% | $24.08B | +303.41% | 0.00% |
| CNC | 0.67% | $29.19B | -21.56% | 0.00% |
| BCAN | 0.70% | $72.87M | -99.75% | 0.00% |
| FCN | -0.70% | $7.10B | -10.74% | 0.00% |
| LTRN | 0.79% | $33.22M | -22.61% | 0.00% |
| RNR | -0.86% | $13.74B | +23.09% | 0.58% |
| NERV | -0.86% | $14.69M | -58.00% | 0.00% |
| K | -0.86% | $27.77B | +52.50% | 2.79% |
| LFVN | -0.88% | $169.84M | +130.61% | 1.10% |
| GSK | -0.90% | $68.24B | -5.43% | 4.71% |
| ACRS | -0.91% | $327.87M | +415.67% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CHD | -20.49% | $27.18B | +19.50% | 1.03% |
| CAH | -18.06% | $28.64B | +12.14% | 1.70% |
| COR | -14.31% | $47.48B | +21.20% | 0.86% |
| MCK | -14.09% | $78.15B | +35.51% | 0.42% |
| TCTM | -12.24% | $8.10M | -42.99% | 0.00% |
| ABT | -11.08% | $203.16B | +14.93% | 1.88% |
| CMG | -10.52% | $80.02B | +33.62% | 0.00% |
| LMT | -10.33% | $126.40B | +18.99% | 2.36% |
| CBOE | -8.87% | $21.46B | +15.84% | 1.11% |
| TILE | -7.93% | $1.45B | +150.00% | 0.16% |
| PRLB | -7.10% | $907.12M | +1.96% | 0.00% |
| MSI | -6.52% | $81.46B | +52.34% | 0.80% |
| PULM | -6.17% | $19.83M | +202.98% | 0.00% |
| BTCT | -5.61% | $42.61M | +353.33% | 0.00% |
| HLN | -5.57% | $42.91B | +13.94% | 1.67% |
| GAN | -5.28% | $83.39M | +21.19% | 0.00% |
| CANG | -5.07% | $253.50M | +212.50% | 0.00% |
| NOC | -5.07% | $71.54B | +4.23% | 1.60% |
| CYCN | -5.07% | $4.77M | -16.19% | 0.00% |
| WAT | -5.06% | $20.47B | +25.51% | 0.00% |
ETF's related to LXRX
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -34.26% | $388.04M | 1.43% |
| VIXY | -22.51% | $195.31M | 0.85% |
| USDU | -16.79% | $201.97M | 0.5% |
| TAIL | -13.28% | $67.98M | 0.59% |
| XBIL | -11.18% | $637.70M | 0.15% |
| UUP | -10.68% | $309.25M | 0.77% |
| TBIL | -9.16% | $4.38B | 0.15% |
| AGZD | -9.14% | $142.76M | 0.23% |
| EQLS | -7.93% | $76.08M | 1% |
| XHLF | -7.82% | $874.27M | 0.03% |
| UNG | -7.03% | $908.80M | 1.06% |
| CORN | -6.75% | $61.12M | 0.2% |
| KCCA | -6.68% | $220.51M | 0.87% |
| CTA | -6.56% | $350.27M | 0.78% |
| KMLM | -5.88% | $353.87M | 0.9% |
| DBA | -5.67% | $755.88M | 0.93% |
| ULST | -5.21% | $535.47M | 0.2% |
| SOYB | -4.90% | $27.32M | 0.22% |
| WEAT | -4.78% | $120.27M | 0.28% |
| FTSD | -2.99% | $171.68M | 0.25% |
News
Yahoo
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth invest
Finnhub
Lexicon Appoints Ivan H. Cheung to Board of Directors THE WOODLANDS, Texas, November 20, 2024 -- Lexicon Pharmaceuticals, Inc. today announced that Ivan H. Cheung has...
Yahoo
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...
Yahoo
Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor classTHE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association’s (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois. One of those studies, a secondary analysis of data from the Phase 3
Yahoo
Lexicon Pharmaceuticals Inc (LXRX) showcases progress in clinical developments and strategic partnerships, while navigating regulatory hurdles and financial pressures.
Yahoo
Lexicon (LXRX) delivered earnings and revenue surprises of -5.88% and 44.18%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.